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Central thyroid hormone signaling is important in brain function/dysfunction, including affective disorders and depression. In
contrast to 3,3󸀠,5-triiodo-L-thyronine (T3), the role of 3,5-diiodo-L-thyronine (T2), which until recently was considered an inactive
metabolite of T3, has not been studied in these pathologies. However, both T3 and T2 stimulate mitochondrial respiration, a
factor counteracting the pathogenesis of depressive disorder, but the cellular origins in the CNS, mechanisms, and kinetics of the
cellular action for these two hormones are distinct and independent of each other. Here, Illumina and RT PCR assays showed that
hippocampal gene expression of deiodinases 2 and 3, enzymes involved in thyroid hormone regulation, is increased in resilience
to stress-induced depressive syndrome and after antidepressant treatment in mice that might suggest elevated T2 and T3 turnover
in these phenotypes. In a separate experiment, bolus administration of T2 at the doses 750 and 1500mcg/kg but not 250mcg/kg in
naive mice reduced immobility in a two-day tail suspension test in various settings without changing locomotion or anxiety. This
demonstrates an antidepressant-like effect of T2 that could be exploited clinically. In a wider context, the current study suggests
important central functions of T2, whose biological role only lately is becoming to be elucidated.
1. Introduction
Despite advances in the pharmacotherapy of depression,
many patients fail to respond to standard antidepressants.
This requires new treatment and augmentation approaches
to be developed. Further elaboration of a potential of the
brain thyroid system to be targeted to elicit an antidepressant
action can be one of the most promising strategies. Central
thyroid hormone synthesis was demonstrated in the dentate
gyrus of the hippocampus, the septum, amygdala, and the
olfactory bulb [1–5]. The action of thyroid hormones in the
CNS is considered to be independent of peripheral thyroid
hormones [5–7]. At very low doses, brain thyroid hormones
induce profound effects on the CNS. For example, they
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enhance hippocampal neurogenesis [8] and the secretion
of neurotrophins, including BDNF, either directly or via
monoamine receptors, and they activate PI3 K-Akt signal-
ing through integrin receptors [9–11]. Deficiency of brain
thyroid hormone production contributes to reduced central
serotonin activity and development of depression [6, 12].
A number of studies suggest that both 3,3,5-triiodo-
L-thyronine (T3) and 3,5,3󸀠,5󸀠-tetraiodo-L-thyronine (T4)
thyroid hormones could be promising adjunct therapy
in patients refractory to tricyclics and selective serotonin
reuptake inhibitors (SSRI) [13, 14]. Hitherto, it was not
clear whether 3,5-diiodo-L-thyronine (T2), which has been
recently identified as functionally active metabolite of T3 in
periphery in in vivo and in vitro systems, might have similar
effects to T3 that might be exploited in a clinic. New evidence
does suggest that T2maymediate the effects of antidepressant
therapy in the brain. A two-week intraperitoneal adminis-
tration of the tricyclic antidepressant desipramine in the rat
induces the expression of T2 in the amygdala [2]. This was
paralleled by increased concentrations of T3 in nuclei but
in contrast to T2 expression not in the mitochondria. These
desipramine-induced changes in T2 were accompanied by an
increase in the concentrations of succinate dehydrogenase
in the mitochondria, suggesting their elevated functional
activity [2]. Other experiments of the same group [1] have
shown the presence of metabolites of T2 in several brain
areas including the hippocampal formation and septum
that points to the occurrence of T2 itself in the limbic
system. Extensive study of Eravci and coworkers [15] has
shown significant changes in the hippocampal formation
and amygdala in the key enzymes regulating the levels of
thyroid hormones, deiodinases 2 (DIO2) and 3 (DIO3) of the
rats which were dosed with antidepressant and antipsychotic
agents or subjected to a 24 h sleep deprivation, a commonly
used nonpharmacological antidepressant treatment. Thus
changes in the levels of thyroid hormones by their synthesis
or degradation in the limbic system generally and in the
hippocampus in particular are implicated in depressive traits
and antidepressant response.
T2 was recently found to increase resting metabolic
rate and prevent diet-induced insulin resistance through the
stimulation of the mitochondrial respiratory chain; the latter
mechanism is in itself an emerging target of new antidepres-
sant therapies [16–21]. These and other studies have revealed
intriguing cellular effects of T2 that seem to be distinct from
that of T3. Unlike T3, T2 enhances mitochondrial respiration
by a nuclear-independent mechanism and neither does act
via thyroid hormone receptor beta, nor via AMP-activated
protein kinase. T2 was demonstrated to activate reactions
involved in substrate oxidation, affecting both cytochrome c
reducers and cytochrome c oxidizers [20, 21], and besides it
effects on respiratory chain, it was suggested to increase the
downstream mechanisms that are involved in mitochondrial
biogenesis [17]; these andother effects of T2 onmitochondrial
pathways were shown to be distinct from the effects of T3
[22]. In contrast to the lasting l effects of T3 on metabolic
rate and mitochondrial respiration, with onset delayed for
48 h, the action of T2 appears within the first few hours and
does not persist for longer than 48 h and is not sensitive to
actinomycin D [5, 20, 22]. T2 was found to evoke selective
thyromimetic activity in vitro and in vivo that is divergent
from that of T3 [23]. This and other mounting evidence,
suggest that the effects of T2 do not merely mimic those of
T3 but, instead, involve distinct mechanisms that seem likely
to be related to stimulatory action on mitochondria.
Intriguingly, there is growing evidence to suggest that
antidepressants can stimulate the mitochondrial respiratory
chain directly and indirectly and suggest that these effects are
implicated in the stress response and the pathogenesis of a
depressive-like state. For instance, thiazolidinediones, which
act as potent sensitizers of the neuronal insulin receptor,
enhance brain glucose utilization though increased neuronal
mitochondrial biogenesis [24], decrease neuronal damage
[25], induce an antidepressant-like effect in the tail suspen-
sion and forced swim tests in mice [26], and show clinical
efficacy in patients withmajor depression [27, 28]. Our recent
studies on mice have indicated that dicholine succinate, a





tion of the mitochondrial respiratory chain, decreased signs
of stressed-induced anhedonia in a sucrose test, immobility
in the forced swim model, and hippocampal gene expression
[29].
So far, limited efforts have beenmade to address potential
central functions of T2 using animal models of depression.
The hippocampus, as part of the limbic system, was chosen
as a focus of the present study based on the striking differ-
ences between resilient versus susceptible to stress-induced
depressive-like state mice in the mitochondrial gene expres-
sion of this structure [30, 31]. Using the above-mentioned
paradigm of stress-induced anhedonia in C57BL6J mice,
we addressed whether hippocampal expression of the key
enzymes regulating the levels of thyroid hormones, DIO2
and DIO3, is altered in the hippocampus of animals with
depressive-like features. Separately, we also assessed the
effects of a bolus administration of 3,5-diiodo-L-thyronine
(T2) in mice in the tail suspension test, a common test of
depressive-like behaviour, and in supplementary paradigms
for anxiety and locomotion, such as dark/light and novel cage
tests. The efficacy of the treatment with T2 was evaluated on
two laboratory strains, C57BL6J and CD1mice. A selection of
a two-day tail suspension paradigm as a test for a depressive-
like behavior [32] and of single dosing were based on
previously reported studies, in which T2 induced marked
effects in rats within the first hours after administration [16,
33] and chronic administration of T2 evoked thyromimetic
action in rats [23] that we wished to avoid in our study.
Therefore, T2 was applied to mice intragastrically as a bolus
injection 30min prior to or 2 h after the first test session.
2. Materials and Methods
2.1. Animals and Housing. Male C57BL6J and CD1 mice
were 3-month old. Two–five-month-old Wistar rats of the
same age were used for predator stress. Mice were obtained
from Charles River (Janvier, l’Arbresle Cedex, France) and
rats from the Medical Faculty of New University of Lisbon,
Lisbon, Portugal. 14 days before the behavioural experiments,
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Figure 1: Schematic timeline of the chronic stress (a) and tail
suspension ((b)–(d)) experiments.
mice were single housed under a reverse 12 h : 12 h light-dark
cycle (lights on: 21:00 h) in standard laboratory conditions
(22 ± 1∘C, 55% humidity, food, and water ad libitum).
All experiments were carried out in accordance with the
European Committees Council Directives and had been
approved by the state governmental bodies of animal care and
welfare.
2.2. Chronic Stress Experiment
2.2.1. Experimental Conditions and Study Outline. Parame-
ters of social behaviour were determined one week before
the chronic stress procedure in a social interaction test as
described elsewhere [30, 34, 35]. Body weight and baseline
preference for a 1% sucrose solution (see Sucrose Test) were
recorded (Figure 1(a)). The experimental and control groups
were balanced upon these parameters. Together, 40 mice
were assigned to a stress group and 24 controls constituted
a nonstressed control group. Among animals from a stress
group, twenty mice received no treatment and twenty were
treated with imipramine. Control mice were neither treated
(𝑛 = 14) nor treatedwith imipramine (𝑛 = 10). In control and
stress groups, imipramine (7mg/kg/day) was administrated
via drinking water starting 7 days prior to the onset of stress
and lasting the entire duration of the stress procedure. The
current antidepressant treatment was applied as described
elsewhere [29].
Additionally to baseline measurements, a sucrose con-
sumption test was performed on the 10th day of the chronic
stress procedure. On the next day, mice were tested in the tail
suspension test and scored for a coat disintegration, and their
body weight was evaluated. Five days after the termination of
the stress procedure, mice were sacrificed for gene expression
analysis (Figure 1(a)).
(1) Chronic Stress Procedure. This study uses a recently
validated variant of a 10-day stress protocol [29, 34, 35]
comprising night time rat exposure and day time application
of two stressors: a social defeat and restraint stress. Between
the hours of 10:00 and 17:00, social defeat for 30 minutes
and restraint stress were employed for 2 hours with an inter-
session interval of at least 4 hours.
Rat Exposure While in a Small Container. Mice were intro-
duced to transparent glass cylindrical containers (15 cm
× 0.8 cm) and placed into the rat cage (15 h exposures were
performed between 18.00 and 09.00).
Social Defeat Stress. Social defeat procedures took place
during the dark phase; to enable a visual control over the
resident-intruder confrontation, the test was carried out
under red light. In a preliminary test, aggressive individuals
of the CD1 mouse strain that were able to attack the counter
partners in less than 60 sec without injuring them were
selected for this procedure; these animals were introduced
in the home cages of mice from the stress group during
social defeat sessions. Social interaction was set up in the
home cage of stressed animals as it enhances the impact
of the stress procedure in a lasting manner. In a variant
procedure, a defeated animal is left in chronic contactwith the
olfactory cues of the aggressive intruder, such that exposure
to a psychological stressor is chronic, although the actual
agonistic experience is intermittent. Average duration of
each session was 30min in accordance with commonly used
protocols. During social defeat stress, test mice typically
showed flight response, submissive posture, and vocalization.
Pairs of animals were carefully observed in order to exclude
any physical harm. In rare cases of its incidence, aggressive
individuals were immediately removed from the cage of
resident mice.
Restraint Stress. Animals were placed inside plastic tubes
(internal diameter is app. 26mm)during the dark phase of the
light cycle. Small standard pieces of tissue paperwere inserted
in the tubes to restrict animals’ activity.
(2) Assessment of Stress Effects
Sucrose Test. Animals were given 8 hours of free choice
between two bottles of either 1% sucrose or normal drinking
water. At the beginning and end of the period, the bottleswere
weighed and consumption was calculated. The beginning of
the test started with the onset of the dark (active) phase
of animals’ cycle. To prevent the possible effects of side
preference in drinking behaviour, the position of the bottles
in the cage was switched at 4 hours, halfway through testing.
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No previous food or water deprivation was applied before the
test. Other conditions of the test were applied as described
elsewhere [24]. The 1% sucrose solution is used in tests
performed during baseline and chronic stress application.





V (Sucrose solution) + V (Water)
] × 100%.
(1)
A decrease in sucrose preference to a level below 65%
measured at the 10th day of continuous stress application was
taken as a criterion for anhedonia. This criterion was based
on the fact that none of the control animals exhibited <65%
preference for sucrose at that time point of the study and,
accordingly, mice exhibiting a sucrose preference of <65%
were defined as susceptible to stress-induced anhedonia.
Mice that had undergone stress but maintained a sucrose
preference of >65% were defined as resilient to this state. In
addition, our previous results indicated that mice matching
this criterion showed a depressive-like syndrome [35]. This
procedure induces anhedonia in a considerably shorter time
than previously validated models by increasing the daytime
stress load.
Tail Suspension Test. The protocol used in this study was
adapted from a previously proposed procedure [36]. Mice
were subjected to the modified tail suspension by being
hung by their tails with adhesive tape to a rod 50 cm above
the floor for 2min. Two animals were tested simultaneously
in a dark room where only the area of the modified tail
suspension construction was illuminated by a spotlight from
the ceiling; the lighting intensity on the height of the mouse
position was 25 Lux. The trials were recorded by a video
camera positioned directly in front of the mice, while the
experimenter observed the session from a distance in a dark
area of the experimental room. This procedure was carried
out twice with a 24 h interval between tests, similarly to
previously reported protocols [32]. The latency of the first
episode of immobility and the total duration of this behaviour
were scored manually according to the protocol that was
previously validated with automated scoring using CleverSys
software [36]. In accordance with the commonly accepted
criteria of immobility, the immobility behaviour was defined
as the absence of any movements of the animals’ head and
body. The latency of immobility was determined as the time
between the onset of the test and the first bout of immobility.
Coat State Scoring. A coat statewas scored in a blinded fashion
to assess a stress-related disintegration of fur. Scores from
1 (very poor) to 5 (excellent) were assigned to each animal
by two independent experimenters; the average note was
taken. This parameter was earlier shown to correlate with a
development of stress-induced anhedonia as it reflects self-
grooming behaviour that is dependent on hedonic sensitivity
[36].
Brain Dissection, RNA Isolation, and Illumina Microarray
Gene Expression Profiling. Mice were sacrificed by cervical
dislocation. RNA extraction was performed from microdis-
sected snap-frozen hippocampi using RNeasy RNA extrac-
tion kit with DNaseI treatment, as previously described
(Qiagen, Hilden, Germany; [34]).
Gene expression profiling was performed using Illumina
technology (Integragen, Evry, France, and Northwestern
Chicago University, USA) with the hippocampi of mice from
nonstressed control (drug-naive or treated with imipramine),
stressed resilient, and anhedonic groups and from stressed
imipramine-treated mice (five animals per each group were
analyzed). Total RNA samples were hybridized to Illumina
BeadChips (MouseRef-8 v2 Expression BeadChip; Illumina,
Inc. San Diego, CA, USA) which were prepared using
the Illumina TotalPrep RNA Amplification kit (Applied
Biosystems/Ambion, Carlsbad, CA, USA); the samples were
assigned to the chips in random order with the constraint
that no two samples from the same group were assigned
to the same chip to avoid confounding of experimental
groups with the chips. Microarray data were analyzed using
standard analysis procedures, which included assessment of
the overall quality of array data and statistical evaluation
of differentially expressed genes (IntegraGen, Evry, France).
Once the quality of array data was confirmed, the Gene
Chip Operating System (Illumina, Inc., San Diego, CA, USA)
was used to calculate signal intensities, detection calls, and
their associated 𝑃 values for each transcript on the array.
Gene expression was normalized to the expression of the
housekeeping gene, beta-actin, due to its stable expression,
and calculated as percent mean of the respective control
group (pharmacologically naive or treated with imipramine).
Differences in gene expression between groups were evalu-
ated using unpaired two-tailed 𝑡-test.
Real-Time PCR (RT-PCR). 1𝜇g total RNA was converted
into cDNA as described elsewhere [34]. RT-PCR was run
using SYBR green based technology (Primer Design Ltd.,
Southampton, UK). Standard curves were generated using
previously generated samples to enable normalization to the
housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH; forward primer ACCCCTTCATTGACC-
TCAACTACATG; reverse primer CCTTCTCCATGGTG-
GTGAAGAC)using the Pfafflmethod as described elsewhere
[37]. Expression of DIO2 was assessed using a forward
primer GATGCTCCCAATTCCAGTGT and reversed prim-
er TGAACCAAAGTTGACCACCA; expression of DIO3was
assessed using a forward primer CCGCATATGGTGCC-
TATTTT and reversed primer GCCCACCAATTCAGT-
CACTT. All samples were run in duplicate. Cycling was
performed at 95∘C for 5min followed by a 45 cycle ampli-
fication at 95∘C for 10 s, then at the annealing temperature
for 15 s and at the temperature 72∘C for 20 s. Results of the
qPCR measurements were expressed as Ct values, where Ct
is defined as the threshold cycle of PCR at which amplified
product was 0.05% of normalized maximal signal. We used
the comparative Ct method and computed the difference
between the expression of the gene of interest and GAPDH
expression in each cDNA sample (2-ΔΔ Ct method). Results
are expressed as relative-fold change compared to control
animals.
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2.3. Tail Suspension Experiment. On the basis of gene expres-
sion data, the further aim of our study is to examine the
effects of bolus T2 administration on the immobilization
behaviour in the tail suspension test in C57BL6J and CD1
mice. Supplementary tests for anxiety-like behaviour and
locomotion were carried out on the same mouse strains in
order to rule out potential confounds with the evaluation of
behavioural despair after the treatment with T2.
First, we investigated the effects of a bolus oral gavage of
T2 (see drug administration below) to C57BL6J mice at the
dose of 250mcg/kg either 30min before (𝑛 = 7) or 2 h after
(𝑛 = 8) the first tail suspension session of the test (Figures
1(b) and 1(c)), as described previously [26, 32, 36]; control
groups constituted 8 mice in each experiment. Second, T2
was used at the dose of 750mcg/kg prior to the tail suspension
session (𝑛 = 8) or 2 hrs thereafter (𝑛 = 8); control groups
constituted 8mice. Finally, a dose of 1500mcg/kg was applied
30min prior to the first tail suspension session in CD1 mice
(𝑛 = 10); control group was formed by 10 mice. The same
vehicle was injected into controls. A selection of doses of T2
and the timing of dosing were based on previously reported
studies, in which it induced marked effects in rats within the
first hours after administration [16, 33].
In an additional study, we addressed the question of
whether the administration of 750mcg/kg of T2 in C57Bl6J
and 750mcg/kg of T2 or 1500mcg/kg of this drug in CD1
mice interferes with anxiety and locomotion in a dark/light
and novel cage tasks in previously calibrated protocols [36,
38, 39]. Dark/light and novel cage tasks were applied with a
5min interval 30min after a dosing (Figure 1(d)). All groups
constituted 9 mice.
2.3.1. Dark/Light Box. The dark/light box (TechnoSmArt,
Rome, Italy) consisted of two plexiglass compartments, one
black/dark (15 cm × 20 cm × 25 cm) and one lit (30 cm
× 20 cm × 25 cm), connected by a tunnel. Anxiety-like
behaviour was assessed by earlier validated measures. Mice
were placed into the dark compartment, from where they
could visit the lit box (light intensity 25 Lux). The latency
of the first exit to the light compartment, the total duration
of time spent in the lit box, and the number of visits
to this anxiety-related compartment were scored by visual
observation over 5min.
2.3.2. Novel Cage Test. The novel cage test was performed to
assess vertical activity [35, 36, 39]. Mice were introduced into
a standard plastic cage; the size of their home cage filled with
small amounts of fresh sawdust. The number of exploratory
rearings was counted under red light during a 5min period.
The testing was carried out in a dark quiet room in morning
hours. Behaviour was videotaped and analyzed by trained
observers blind to the animals’ treatment.
2.3.3. Drug Administration. Imipramine (Sigma-Aldrich, St.
Louis, MO, US) was dissolved in tap water; the solution
was freshly prepared every 2-3 days and placed in lightproof
drinking bottles. The calculation of the concentration of
imipramine in drinking water was based on the previously
evaluated mean volume of daily water consumption in
C57BL6 mice that was about 3mL and on the dosage of
treatment. Dosage for imipramine was set at 7mg/kg/day
as previous studies showed that chronic administration of
imipramine at 15mg/kg/day with drinking water, but not
7mg/kg/day, significantly affects sucrose intake and loco-
motor behaviour in naive C57BL6N mice [39]. Imipramine
was delivered with drinking water starting 1 week before the
onset of stress and then throughout the entire duration of the
chronic stress procedure.
3,5-Diiodo-L-thyronine T2 (Sigma-Aldrich, Cambridge,
MA, USA) was first dissolved in 100% DMSO (Sigma-
Aldrich, St. Louis, MO, US), the solution was diluted, so the
final concentration of DMSO that was 0.2% and adminis-
trated to mice via a single intragastrical administration. The
same treatment method was applied to administer a vehicle
0.2% DMSO solution. A separate control group of mice
was injected with saline; no effects of 0.2% DMSO solution
were found in protocols applied here of the tail suspension
tests (Strekalova and Chernopiatko, unpublished results). The
volume of T2 and vehicle injections was 0.1mL/10 g of body
weight.
2.4. Statistics. Data were analysed with GraphPad Prism
version 5.00 for Windows, San Diego, CA. One- and two-
way ANOVA were used followed by a Mann-Whitney 𝑈-
tests posthoc comparisons. Two-tailed unpaired 𝑡-tests were
applied for two-group, two-tailed comparisons of indepen-
dent data sets with normal distribution. The level of confi-
dence was set at 95% (𝑃 < 0.05) and data are shown as mean
± SEM.
3. Results
3.1. Assessment of Anhedonia Induction. In the model
employed, the induction of a depressive-like state by stress
exposure was defined by the occurrence of behavioural
manifestations of anhedonia, as determined by a decrease in
preference for a 1% sucrose solution to below 65% [35]. Previ-
ous studies have shown that the occurrence of stress-induced
anhedonia is associated with a number of behavioural,
physiological andmolecular features of a depressive state [29–
31, 34–36].
When assigned to experimental groups, but before being
subjected to the chronic stress procedure, groups did not dif-
fer in terms of sucrose preference, intake of sucrose solution
and water, or body weight (𝑃 > 0.05; one-way ANOVA;
data not shown). Two-way ANOVA revealed a significant
effect of stress on sucrose preference (𝐹
1,59
= 7.671; 𝑃 =
0.0075). A Post hoc Mann-Whitney test showed a significant
difference in sucrose preference between control and the
nontreated stressed group (𝑈 = 47.00; 𝑃 = 0.0012), but
when treated with imipramine there was no difference from
control and stressed groups in terms of sucrose preference
(𝑈 = 135.0; 𝑃 = 0.8748). This suggests that imipramine
prevents the reduction in sucrose preference for the stressed
cohort (Figure 2(a)). 60% of nontreated stressed mice (12 out
of 20) and 25% of imipramine-treated stressed animals (5
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Figure 2: Chronic stress induces physiological and behavioural changes in a subgroup of anhedonic mice, which are not evident in mice
resilient to stress. (a) A loss of sucrose preference was used to define the susceptible group, which was measured after the termination of a
10-day stress paradigm. (b) Latency to immobility in the tail suspension test was significantly shorter in stressed drug-naive animals than in
control and stressed imipramine-treated groups. (c)The duration of immobility in the tail suspension test was significantly longer in stressed
drug-naive than in control and stressed imipramine-treated groups. (d) In comparison to control mice, the score of coat state was significantly
decreased in stressed nontreatedmice and, to lesser extent, in stressed imipramine-treated animals. (e) Body weight was significantly reduced
in both stressed group; it was significantly higher in imipramine-treated than in nontreated stressed groups. Data aremean ± SEM; ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001; TST: tail suspension test.
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out of 20) showed a sucrose preference below 65% and were
defined as anhedonic (susceptible).
3.2. Effects of Treatment on Immobility Behaviour. Previous
studies have shown that stress-induced anhedonia, measured
by the sucrose preference test, is frequently associated with
increased “behavioural despair” in the Porsolt forced swim
and tail suspension paradigms [40]. Onset of immobility
(behavioural despair) in the latter model is defined as the
point at which the animal stops struggling for longer than
1 second. Latency to immobility was significantly altered
by stress as revealed by two-way ANOVA (𝐹
1,49
= 17.70;
𝑃 = 0.0001). Post hoc Mann-Whitney tests showed a strong
trend towards a significant reduction in latency to immobility
for stressed nontreated animals compared with control mice
(𝑈 = 60.50; 𝑃 = 0.0889); there was no significant
difference between stressed and control mice that received
imipramine (𝑈 = 76.50; 𝑃 = 0.2213; Figure 2(b)). Time
spent immobile showed a significant main effect of stress
(𝐹
1,49
= 24.79; 𝑃 < 0.0001); stressed mice were immobile
for significant longer than controls (Figure 2(c)). Posthoc
analysis showed significant differences between control and
stressed nontreated groups (𝑈 = 27.00; 𝑃 = 0.0012) but
not between control and stressed imipramine-treated group
(𝑈 = 67.50; 𝑃 = 0.1056) suggesting that applied treatment
prevents the behavioural despair induced by the chronic
stress paradigm.
3.3. Evaluation of Coat Scores. Before the onset of the chronic
stress procedure, all mice had good coat quality, with no
significant difference between the groups (data not shown).
After completion of the chronic stress procedure, a two-
way ANOVA comparison showed significant main effects of
both stress (𝐹
1,60
= 125.8; 𝑃 < 0.0001); and treatment
(𝐹
1,60
= 8.416; 𝑃 = 0.0052; Figure 2(d)). All stressed mice
showed significantly lower scores of coat state than control-
treated animals (𝑃 < 0.001). However, imipramine-treated
animals exhibited higher scores of coat state compared with
the nontreated group (𝑈 = 80.00; 𝑃 = 0.0009).
3.4. Changes in Body Weight. At the end of the chronic stress
paradigm, there was a significant difference in body weight
between control and stressed animals (two-way ANOVA;
𝐹
1,60
= 65.39; 𝑃 < 0.0001), and stressed drug-naive group
showed a significant decrease in body weight compared with
controls (𝑈 = 21.5, 𝑃 < 0.0001 for stressed nontreated
animals), while imipramine-treated mice did not show such
a change (𝑈 = 100.5; 𝑃 = 0.1718; Figure 2(e)). Stressed mice
treated with an antidepressant were significantly heavier than
those that were not treated pharmacologically (𝑈 = 111.5;
𝑃 = 0.0172; Figure 2(e)).
3.5. Expression of Genes Encoding Deiodinases 2 and 3 in the
Hippocampus of Stressed Mice. There was a trend towards
elevatedDIO2 expression for resilient versus susceptiblemice
as shown by Illumina microarray analysis (𝑃 = 0.10; 𝑡 =
1.362, df = 6; unpaired 𝑡-test; Figure 3(a)), and RTPCR
revealed an increase in DIO2 expression in resilient versus
susceptiblemice (𝑈 = 2.000;𝑃 = 0.0488;Mann-Whitney test;
Figure 3(c)). Both Illumina profiling and RTPCR assays have
shown that DIO2 was significantly augmented in the stressed
imipramine-treated group in comparison with stressed drug-
naive animals (𝑃 = 0.04; 𝑡 = 1.797; df = 16; 𝑡-test and
𝑈 = 3.000; 𝑃 = 0.0424; Mann-Whitney test, resp.; Figures
3(b) and 3(d)). There was a trend toward elevated DIO3
expression for resilient versus anhedonic mice as shown
by Illumina assay (𝑃 = 0.11; 𝑡 = 0.9755; df = 7; 𝑡-
test; Figure 3(e)) and RTPCR analysis (𝑈 = 3.000, 𝑃 =
0.1250; Mann-Whitney; Figure 3(g)). Illumina microarray
has demonstrated a nonsignificant increase in the DIO3
expression in imipramine-treated animals over this measure
in stressed drug-naive group (𝑃 = 0.137; 𝑡 = 1.557; df =
18; 𝑡-test; Figure 3(f)). Following this trend, RTPCR revealed
significantly elevated level of DIO3 expression in the stressed
imipramine-treated group in comparison with stressed drug-
naive animals (𝑈 = 3.000; 𝑃 = 0.0420; Mann-Whitney test,
resp., Figure 3(h)). Of note, in control nonstressed mice, the
expression did not differ for either gene between drug-naive
and imipramine-treated groups (data not shown).
3.6. 3,5-Diiodo-L-Thyronine T2 Reduces Immobility Time in
the Tail Suspension Test. The parameters of immobility in
mice dosed with 250mcg/kg of T2 in either protocol of the
tail suspension test were unaltered (Figures 4(a) and 4(b)).
C57BL6J and CD1 mice dosed prior to the first testing with
750mcg/kg or 1500mcg/kg, respectively, had significantly
reduced immobility on Day 1 (𝑃 = 0.008, 𝑡 = 3.076, df = 14
and𝑃 = 0.025, 𝑡 = 2.089, and df = 18) andDay 2 (𝑃 = 0.0205,
𝑡 = 3.327, df = 14 and 𝑃 = 0.0096, 𝑡 = 2.572, df =
18; Figure 4(e)). There was a tendency to longer latency of
immobility during thesemeasurements; a significant increase
was found onDay 2 of testing ofmice treatedwith 750mcg/kg
(𝑃 = 0.0169, 𝑡 = 2.352, df = 14). Animals that received T2 at
the dose 750mcg/kg of T2 after the first test session showed
a tendency to decreased immobility (𝑃 = 0.0734, 𝑡 = 1.536,
and df = 14) and significantly increased latency of immobility
(𝑃 = 0.006, 𝑡 = 2.840, df = 14) on Day 2; experimental
groups have displayed no behavioural differences prior to the
treatment, on Day 1 (Figure 4(c)).
Dosing with 750 or 1500mcg/kg did not alter anxiety-
like behaviour of C57Bl6J mice (data not shown) and CD1
mice, as shown by unaffected latencies of the first exit to
the lit compartment (one-way ANOVA, 𝐹 = 0.4640, 𝑅2 =
0.0662, and𝑃 = 0.6388; Figure 5(a)), time spent therein (one-
way ANOVA, 𝐹 = 2.390, 𝑅2 = 0.2688, and 𝑃 = 0.1307;
Figure 5(b)), and number of exits (one-way ANOVA, 𝐹 =
0.07238, 𝑅2 = 0.01101, and 𝑃 = 0.9305; Figure 5(c)). The
number of rearings was unaltered (one-way ANOVA, 𝐹 =
0.1395, 𝑅2 = 0.02101, and 𝑃 = 0.8711; Figure 5(d)).
4. Discussion
The present study highlights hippocampal gene expression of
DIO2 and DIO3, enzymes involved in the thyroid hormone
regulation, as a molecular correlate of antidepressant-like
effects in a stress-induced depressive syndrome in mice. The
8 BioMed Research International
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Figure 3: Hippocampal gene expression of deiodinases 2 and 3 in a chronic stress depression model. Illumina assay has pointed to (a) a
nonsignificant decrease in DIO2 expression in susceptible versus resilient mice and (b) significant elevation of DIO2 expression in stressed
imipramine-treated group in comparison with stressed drug-naive animals. RTPCR analysis showed a significant (c) decrease in DIO2
expression in susceptible versus resilient mice and (d) increase in DIO2 expression in stressed imipramine-treated group in comparison
with stressed nontreated mice. As for DIO3 expression, Illumina assay has revealed no significant differences in its expression between (e)
susceptible versus resilient mice and (f) stressed imipramine-treated stressed drug-naive groups. RTPCR analysis demonstrated a lack of
significant differences with the former comparison (g), but (h) showed a significant increase in DIO3 expression in stressed imipramine-
treated group in comparison with stressed nontreated mice ∗𝑃 < 0.05.
present study also identifies increased hippocampal gene
expression ofDIO2 alone in the stress resilient cohort ofmice.
While these changes in enzyme expression levels may not
necessary generate elevated levels of central thyroid hormone,
the ability of administrated T2 to reverse parameters of
behavioural despair supports the hypothesis for T2 as a
contributor to antidepressant activity and suggests that the
administration or augmentation of T2 production may be of
value in the clinic.
Stress-induced anhedonia inmice [34, 35, 40] resulting in
decreased intake or preference for palatable solutions (such
as a sucrose solution) is interpreted as a decreased ability
to experience pleasure, a core feature of human depression
[41]. The stressed mice treated with imipramine in this
study retained a sucrose preference, which is in agreement
with reports from our lab and others, that conventional
antidepressant treatments are able to prevent the stress-
induced decrease in sucrose preference [29, 42, 43]. In
addition to the effects on sucrose preference, we showed that
treatment with imipramine had antidepressant-like effects in
the tail suspension test, and coat state was also improved
by imipramine. Coat disintegration in rodents is due to
reduced motivation for self-cleaning and is used as an
important feature of a depressive-like state in preclinical
models [44]. Improvements in coat state have accordingly
been documented for antidepressant treatments in rodent
models of depression [36, 40, 42]. Imipramine diminished
stress-induced loss of body weight. It has been previously
shown that antidepressant treatment results in a restoration
of body weight [40, 42, 43]. Thus it can easily be argued
that imipramine, at the dose employed, has been effective
as an antidepressant as a consequence of the improvement
observed in all of these outcomes. This is of note because we
used a much lower dose than has been used by convention.
The use of a lower dose was indicated after we showed that
higher doses of imipramine are associated with significant
side effects in naive animals [39]. Such side effects might have
been expected to confound our experimental outcomes, and
thus it was important to be able to validate this lower dose.
Illumina microarray data and our RTPCR assays sug-
gested elevated hippocampal gene expression of DIO2,
encoding a key enzyme of the synthesis of T2 and T3
hormones, in stressed mice that received imipramine and
in stressed mice that are resilient versus mice susceptible
to depressive syndrome. RTPCR also showed a significant
increase in DIO3 expression in stressed imipramine-treated
mice, but no other group differences were significant. As
DIO2 is an enzyme of thyroid hormone synthesis in the
brain, DIO3 inactivates thyroid hormones, and simultaneous
activation of both biosynthesis and degradation of neuro-
chemically active factors often accompanies their enhanced
turnover. In line with our findings, subchronic antidepres-
sant and antipsychotic treatments in a rat induced more
pronounced brain changes of DIO2 than of DIO3, which
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Figure 4: 3,5-diiodo-L-thyronine T2 reduces immobility time in the tail suspension test. On Day 1 and 2 of the tail suspension test, mice
treated with 250mcg/kg of T2 30min before (a) or 2 h after (b) the first session of testing showed no differences in the latency of immobility
and in the duration of this behaviour. (c) Mice treated with 750mcg/kg of T2 30min prior to the first test session had a trend towards
longer latency of immobility on Day 1 and significant increase in this parameter on Day 2; the duration of immobility was significantly
reduced. (d) Animals that received the dose of 750mcg/kg of T2 2 h after the first session of testing had significant increase in the latency of
immobility on Day 2, and the duration of immobility had a tendency to a decrease. On Day 1, prior to treatment, mice from two groups had
similar behavioural scores. (e) Mice dosed with 1500mcg/kg of T2 30min prior to the first test session had a trend towards longer latency of
immobility on Days 1 and 2; the duration of immobility was significantly reduced. ∗𝑃 < 0.05 versus control.














































































Figure 5: 3,5-Diiodo-L-thyronine T2-treated mice display unaltered anxiety-like and locomotor behaviour. In the dark-light box, mice
that were treated with T2 at the dose 750mcg/kg or 1500mcg/kg did not differ from vehicle-treated mice in (a) the time spent in the lit
compartment, (b) latency of exit in the lit area, and (c) number of exits to the lit box. (d) In the novel cage, mice that received T2 at the dose
750mcg/kg or 1500mcg/kg did not differ from vehicle-treated mice in number of rearings. All groups constituted 9 mice.
have occurred in the same direction [15]. In support of our
results, exposure of a rat to 24 h sleep deprivation, commonly
used as nonpharmacological antidepressant treatment, has
increased the activities of DIO2 in the hippocampus and
several more brain structures, without affecting DIO3; of
note, no such changes were found in the amygdala in
these experiments [15]. This study also has shown that
desipramine, an antidepressant that is similar to the one used
here imipramine, has induced dose-dependent increases of
DIO2 in the cortex, whereas no changes in the DIO3 were
observed [15]. Notably, among deiodinases 1, 2, and 3, DIO2
in particular was found to be the highly sensitive to many
different kinds of influence that are believed to be capable
of inducing the changes in thyroid hormone concentrations
in the CNS and neuronal activity [15]. Other studies showed
that mice lacking DIO2 were demonstrated to have deficits
in the hippocampus-dependent learning [45], obesity with
glucose intolerance [46] that is a well-established indicator
of depressive disorder. Since DIO2 gene expression was
increased in our study in resilient (nonanhedonic) mice or
animals that received imipramine, it can be speculated that
elevated synthesis of thyroid hormones in the hippocampus
is associated with resilience to a depressive-like syndrome.
To the best of our knowledge, no such changes in the DIO2
have been reported until now in relation to a susceptibility
to experimentally induced depressive-like status in animal
models of depression.
Our molecular biology results are indicative of altered
central thyroid hormone concentrations, but they are not
conclusive, and direct measurements of T2 and T3 in the
brain are required. However, the RTPCR results prompted
us to investigate the effect of a bolus injection on the immo-
bilization behaviour in the tail suspension test in C57BL6J
and CD1 mice. All the mice treated with T2 prior to the
first test session displayed shortened time spent immobile on
both days of testing. Our results, obtained in two treatment
protocols on two mouse strains, suggest an antidepressant-
like effect of used here dosing with T2. Present data with T2
are in accordance with our previous observations that have
shown more pronounced antidepressant effects of acutely
injected SSRIs and tricyclics, which are administrated prior
to the first session of the tail suspension experiment, than
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afterwards, both in the C57BL6J and CD1 mice (Strekalova,
unpublished results). In most of the cases, the antidepressant-
like action of bolus dosing with conventional antidepressants
is often detectable in mice only on the second testing session.
Here, however, a reduction of a depressive-like behaviour in
T2-treated animals was observed on both Day 1 and Day 2 of
the experiment.
Next, we found that bothC57BL/6J andCD1mice showed
no changes in the parameters of anxiety and locomotion
when treated with T2 at the doses that have elicited a
decrease in the immobility time. Namely, in a classical
mouse paradigm for anxiety-like behaviour [29, 34], the dark-
light box, CD1 mice that were treated with T2 at the dose
750mcg/kg or 1500mcg/kg did not show any signs of altered
parameters of anxiety-like behaviour. In the novel cage, a
sensitive paradigm for minor changes in mouse activity
[38, 39], CD1 mice that received T2 at the dose 750mcg/kg
or 1500mcg/kg did not display any locomotor alternations;
similar results in both tests were obtained in C57BL/6J
(data not shown). This rules out potential confounds in the
evaluation of the antidepressant-like activity of the treatment
with T2 that might interfere with the changes in emotionality
and general locomotor activity.
The antidepressant-like effects of T2 in the tail suspension
paradigm suggest specific brain mechanisms of transport of
peripheral T2. Among several thyroid hormone transporters,
recent studies have identified monocarboxylate transporter 8
(MCT8) molecule as a very active and specific transporter of
all thyroid hormones, T4, T3, and T2, which transports them
with comparable uptake rates at various locations [47] and
is highly expressed in hippocampus, olfactory bulb, cerebral
cortex, amygdale, and choroid plexus [48]. A hypothesis
was derived for the mechanism of the transport of thyroid
hormones from the bloodstream to the brain involving
thyroid hormone transporter synthesized in choroid plexus
and secreted into the cerebrospinal fluid [49]. While several
mechanisms of action of T2 can be proposed, including
above-discussed effects of this hormone on monoamine
and integrin receptors, PI3 K-Akt signaling and TRH, given
accumulated evidences concerning eminent effects of T2 on
the mitochondrial respiratory chain [20, 21], biogenesis [17],
and calcium and NO signalling [22], they are likely to be due
to the enhancement of mitochondrial functions, a validated
target of antidepressant therapy [19].
In conclusion, our data further suggest an importance of
central thyroid hormone signalling in depressive-like changes
that can be targeted to improve available therapy of this
syndrome. Our data also provide support for the translation
of T2 enhancing therapy, perhaps in conjunction with con-
ventional therapy, especially when a rapid therapeutic effect
is relevant and/or metabolic parameters of the patients are
compromised.
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